Clinical trials: Post-stroke Spasticity of the Upper Limb
Post-Stroke Spasticity, Cerebrovascular Accident
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS)…
- Trial name
- NCT00460564
- Testing
- GSK1358820
- Where
- 18 sites in Japan
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Spasticity, Post-Stroke
A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity
This trial is a multicenter, open-label study to evaluate the safety and efficacy of GSK1358820 for treatment in post-stroke subjects with focal wrist, finger and in some cases, thumb spasticity.
- Trial name
- NCT01205451
- Testing
- Botulinum toxin type A
- Where
- 13 sites in China
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Upper Limb Spasticity Post-Stroke
Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke
This study aims to estimate the costs of botulinum toxin A utilization in standard practice for the treatment of upper limb spasticity post-stroke in Portugal.
- Trial name
- P_Dysport_CS (NCT02384330)
- Where
- 3 sites in Portugal
- Volunteers
- 57 people
- Sponsor
- Ipsen
Post Stroke Arm Spasticity
Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After Stroke
The objective of this non-interventional study is to evaluate clinical effectiveness and cost effectiveness of Dysport within the reimbursement scheme called "drug programme" funded by Polish National Health Fund (NHF) for…
- Trial name
- PSAS REGISTRY (NCT02444494)
- Where
- 6 sites in Poland
- Volunteers
- 108 people
- Sponsor
- Ipsen
Spasticity, Muscle
MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity
This study is "A Prospective, Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Treatment of Post Stroke Upper Limb Spasticity".
- Trial name
- NCT03908580
- Testing
- Meditoxin
- Volunteers
- 120 people
- Sponsor
- Medy-Tox
Spasticity
MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity
This study is a randomized, double blind, multi-center, active drug controlled, phase III clinical trial to compare the efficacy and safety of MEDITOXIN® versus BOTOX® in treatment of post stroke upper limb(wrist, finger, thumb)…
- Trial name
- NCT01313767
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Medy-Tox
Stroke, Spasticity
Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity
The purpose of this study is to evaluate the safety and efficacy of Botulax® compared to Botox® reducing upper limb muscle tone in post stroke patients.
- Trial name
- NCT01915459
- Testing
- Botulinum toxin type A(Botulax®), Botulinum toxin type A(Botox®)
- Where
- 6 sites in South Korea
- Volunteers
- 186 people
- Sponsor
- Hugel
Spasticity, Stroke
A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity
Purpose: This study is a Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb(wrist, finger…
- Trial name
- NCT01945684
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 197 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Post Stroke Upper Limb Spasticity
To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb
Investigational Product: LIZTOX inj 100unit(HU-014) Title : Multi Center, Phase III Clinical Trial to Evaluate the efficacy and Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity Sites and investigators …
- Trial name
- HU-014 (NCT05289921)
- Testing
- HU-014 Inj
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Huons Co., Ltd.
Upper Limb Spasticity Post-Stroke
Phase 1 Trial of JTM201 in Subjects With Post-stroke Upper Limb Spasticity
Phase 1 trial to evaluate the safety and efficacy of JTM201 compared with 'Botox® Inj.' in subjects with post-stroke upper limb spasticity
- Trial name
- NCT07292025
- Testing
- JTM201 in normal saline, BOTOX 100U in normal saline
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Jetema Co., Ltd.
Upper Limb Spasticity
Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe.
- Trial name
- NCT05956509
- Testing
- ABBV-950, BOTOX
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbbVie
Muscle Spasticity
Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity
Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity.
- Trial name
- NCT02757404
- Testing
- Ultrasonography guidance injection of Meditoxin®., Electrical stimulation guidance injection of Meditoxin®., Manual needle placement injection of Meditoxin®.
- Volunteers
- 59 people
- Sponsor
- Medy-Tox
Upper Limb Spasticity
Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
This is a randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After…
- Trial name
- JUNIPER (NCT03821402)
- Testing
- DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U
- Where
- 26 sites in United States
- Volunteers
- 83 people
- Sponsor
- Revance Therapeutics, Inc.
Spasticity
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total…
- Trial name
- LANTIMA (NCT04752774)
- Testing
- Corabotase, Dysport
- Where
- 81 sites in United States, Austria and 12 more
- Volunteers
- 240 people
- Sponsor
- Ipsen
Spasticity
ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity
The objective of this study is to evaluate the effectiveness of BoNT-A on functional improvement in patients with post-stroke upper and/or lower limb spasticity in the early stage of spasticity development, according to routine…
- Trial name
- ETREAT (NCT02275312)
- Where
- 17 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Ipsen
Post-stroke Arm Spasticity
Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)
Botulinum toxin A (BoNT-A) is effective and safe in alleviating post-stroke spasticity and reducing the burden of associated symptoms.
- Trial name
- EARLYBIRD (NCT01840475)
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Ipsen
Post-stroke Spasticity of the Upper Limb
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the upper limb are effective in treating spasticity in patients after stroke.
- Trial name
- PURE (NCT01392300)
- Testing
- IncobotulinumtoxinA (400 Units)
- Where
- 47 sites in United States, Czechia and 5 more
- Volunteers
- 317 people
- Sponsor
- Merz Pharmaceuticals GmbH
Post-stroke Upper Limb Spasticity
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin.
- Trial name
- NCT00432666
- Testing
- IncobotulinumtoxinA (Xeomin)
- Where
- 3 sites in Czechia, Hungary and 1 more
- Volunteers
- 148 people
- Sponsor
- Merz Pharmaceuticals GmbH
Cerebrovascular Accident
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
This trial is a multicenter, double-blind, randomized, placebo-controlled study to compare GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") with placebo on the efficacy and safety of treatment in…
- Trial name
- NCT01153815
- Testing
- GSK1358820(Botulinum toxin type A)
- Where
- 13 sites in China
- Volunteers
- 170 people
- Sponsor
- GlaxoSmithKline
Spasticity, Post-Stroke
A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity
Botulinum toxin A (GSK1358820) is a sterile, purified type A botulinum neurotoxin complex. In Japan, 240 units of botulinum toxin A are approved as a maximum dose per administration for upper limb spasticity.
- Trial name
- NCT03261167
- Testing
- Botulinum toxin A (GSK1358820)
- Where
- 38 sites in Japan
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline